U.S. FDA Approves Bimekizumab-bkzx (Bimzelx, UCB) for HS
The Dermatology Digest
NOVEMBER 20, 2024
Bimekizumab, an interleukin 17F (IL-17F) and IL-17A blocker, is now the third medication approved for HS, joining adalimumab (Humira, AbbVie) and its biosimilars and secukinumab (Cosentyx, Novartis). The safety profile of bimekizumab was consistent with safety data seen in previous trials across indications with no new safety signals.
Let's personalize your content